https://clinicaltrials.gov/ct2/show/NCT04456673?type=Intr https://clinicaltrials.gov/ct2/show/NCT04456673?type=Intr&cond=COPD&sfpd_d=14&sel_rss=new14 Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation Condition : Chronic Obstructive Pulmonary Disease Interventions : Drug: Dupilumab SAR231893; Drug: Inhaled Corticosteroid; Drug: Inhaled Long-Acting Beta Agonist; Drug: Inhaled Long-Acting Muscarinic Antagonist; Drug: Placebo Sponsors : Sanofi; Regeneron Pharmaceuticals Recruiting NCT04456673 Thu, 02 Jul 2020 12:00:00 EDT
Phase 3
A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)
https://clinicaltrials.gov/ct2/show/NCT02518139?type=Intr&cond=COPD&phase=01234&lupd_s=12%2F17%2F2018&lupd_d=14&sort=nwst A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD) Condition : Chronic Obstructive Pulmonary Disease (COPD) Interventions : Drug: TD-4208; Drug: Tiotropium Sponsor : Theravance Biopharma Completed NCT02518139 Fri, 07 Aug 2015 12:00:00 EDT
Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)
https://clinicaltrials.gov/ct2/show/NCT02459080?type=Intr&cond=COPD&phase=01234&lupd_s=12%2F17%2F2018&lupd_d=14&sort=nwst Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD) Condition : Chronic Obstructive Pulmonary Disease (COPD) Interventions : Drug: TD-4208; Drug: Placebo Sponsor : Theravance Biopharma Completed NCT02459080 Mon, 01 Jun 2015 12:00:00 EDT